CATNAP MI for Obstructive Sleep Apnea

(CATNAP Trial)

Overseen By Madison B Ramos, BA

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Washington State University

Disqualifiers: Living with participant, Cognitive decline, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

Duration: 9 months

140 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a new approach, called CATNAP MI, can help American Indian elders with sleep apnea adhere to their treatment and potentially reduce their risk of Alzheimer's disease. Participants will either continue with their usual care, which includes using a PAP machine for sleep apnea, or try the additional CATNAP MI program. The program provides motivational interviews and electronic messages to support treatment adherence. The trial seeks American Indian elders aged 50 and older, diagnosed with sleep apnea, and currently prescribed PAP therapy. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance treatment adherence and health outcomes.

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What prior data suggests that the CATNAP MI intervention is safe for addressing obstructive sleep apnea?

Research has shown that specific safety data for CATNAP MI, the treatment under study for obstructive sleep apnea (OSA) in this trial, is not available. However, since the study focuses on motivational interviewing and electronic messaging rather than a new drug or surgery, it is likely safe. This approach typically involves discussing issues and offering support, which generally carries minimal risk.

For those considering joining this trial, the goal is to assist participants in adhering to positive airway pressure (PAP) therapy, a common and generally well-tolerated treatment for OSA. While the intervention is new, it employs well-known and safe methods. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Most treatments for obstructive sleep apnea (OSA) involve using a continuous positive airway pressure (PAP) machine to keep the airway open during sleep. However, the CATNAP MI approach is unique because it combines Motivational Interviewing sessions with electronic messaging to enhance adherence to PAP therapy. This method specifically targets the challenges of sticking to PAP treatment and addresses broader health risks like Alzheimer's disease and related dementias. Researchers are excited about CATNAP MI because it not only supports the practical side of using PAP but also engages patients in a way that could improve long-term health outcomes, particularly for American Indians.

What evidence suggests that the CATNAP MI intervention is effective for obstructive sleep apnea?

Research has shown that using a CPAP machine can significantly reduce symptoms of obstructive sleep apnea (OSA), such as excessive daytime sleepiness. CPAP keeps airways open during sleep, improving sleep quality. Studies have found that better sleep can also enhance overall health and quality of life. In this trial, the CATNAP MI program, part of the intervention group, provides additional support through motivational talks and electronic messages to encourage adherence to CPAP therapy. This approach aims to increase CPAP use, potentially lowering the risk of Alzheimer's disease and related dementias. Early findings suggest that regular CPAP use may not only improve sleep but also enhance brain function in people with OSA. ^{1 6 7 8 9}

Are You a Good Fit for This Trial?

The CATNAP study is for American Indian Elders aged 50 or older with obstructive sleep apnea (OSA) who are already using PAP therapy. Participants must be able to understand English and follow the study's procedures.

Inclusion Criteria

I am 50 years old or older.

I use a PAP device for my sleep therapy.

I am willing and able to follow all study procedures.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive usual care with PAP therapy or usual care plus the CATNAP MI intervention, including Motivational Interviewing sessions and electronic messaging to support PAP adherence

9 months

Data collected at baseline, 3-months, and 9-months

Follow-up

Participants are monitored for PAP adherence and cognitive function outcomes

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• CATNAP MI

Trial Overview

This trial tests a new approach called CATNAP MI, which combines motivational interviewing and electronic messaging, aiming to improve OSA treatment adherence and reduce Alzheimer's risk among Native American elders.

How Is the Trial Designed?

Group I: Intervention Group Experimental Treatment 1 Intervention

The CATNAP MI intervention consists of 3 Motivational Interviewing sessions to address obstructive sleep apnea (OSA), positive airway pressure (PAP) adherence, and risk of Alzheimer's disease and related dementias (ADRD) in American Indians and electronic messaging to support PAP adherence, and usual care. Data will be collected at baseline, 3-months, and 9-months.

Group II: Waitlist Control Group Active Control 1 Intervention

Usual care, consisting of an in-service on how to operate the PAP machine, and a mask fitting to select the most comfortable, effective mask for the individual. After 4-6 weeks of use, the participant will be contacted by Missouri Breaks Durable Medical Equipment to review objective adherence data and address any challenges or barriers to therapy such as treatment-emergent central apneas. Data will be collected at baseline, 3-months, and 9-months.

Who Is Running the Clinical Trial?

Washington State University

Lead Sponsor

Trials

114

Recruited

58,800+

Missouri Breaks Industries Research, Inc.

Collaborator

Trials

8

Recruited

2,100+

University of Washington

Collaborator

Trials

1,858

Recruited

2,023,000+

University of Minnesota

Collaborator

Trials

1,459

Recruited

1,623,000+

University of Miami

Collaborator

Trials

976

Recruited

423,000+

Published Research Related to This Trial

In a study of 502 patients over one year, 1-2% experienced serious complications from CPAP and BIPAP treatments for sleep-related breathing disorders, including long central apneas and severe hypoxemia.

Mask leakages and central apneas were common issues that could lead to ineffective therapy, highlighting the need for initial treatment to be conducted in controlled sleep laboratory settings to ensure patient safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Errors and risks in administration of nasal respiratory therapy of obstructive sleep apnea]. Stammnitz, A., Becker, H., Schneider, H., et al.[2016]

In a study of 105 patients with obstructive sleep apnoea (OSA) who experienced an acute myocardial infarction (AMI), 18.4% developed major adverse cardiac events (MACE) over a 5-year follow-up, primarily linked to non-culprit lesions rather than the initial culprit lesion.

Among the 18 patients who experienced MACE, 12 had reinfarctions and 6 required repeat revascularization, indicating that OSA may contribute significantly to the progression of coronary artery disease beyond the immediate effects of the initial heart attack.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Culprit versus non-culprit lesion related adverse cardiac events in patients with obstructive sleep apnoea. Li, R., Loh, K., Loo, G., et al.[2020]

Treatment for obstructive sleep apnea significantly reduces daytime sleepiness, which is a common symptom of the condition.

The study suggests that while daytime sleepiness improves, further research is needed to determine if treatment also enhances other health outcomes related to obstructive sleep apnea.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of OSA: What (else) can it accomplish? Sorsby, SC., Kraleti, S., Jarrett, D.[2020]

In a study of 1860 Chinese subjects with obstructive sleep apnea (OSA) followed for an average of 8.3 years, the time spent with oxygen saturation below 90% (TST90) was found to be a significant predictor of major adverse cardiovascular events (MACEs), while the apnea-hypopnea index (AHI) was not.

Among a subgroup of 333 patients with moderate to severe OSA who were younger and more obese, regular CPAP treatment was associated with a reduced risk of MACEs, highlighting that certain clinical phenotypes may benefit more from CPAP therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cardiovascular outcomes in obstructive sleep apnoea and implications of clinical phenotyping on effect of CPAP treatment. Xu, PH., Fong, DYT., Lui, MMS., et al.[2023]

In a study of 41 non-diabetic patients who had a ST-segment elevation myocardial infarction, those with more severe obstructive sleep apnea (higher apnea-hypopnea index) were more likely to experience major adverse cardiac events over a 5-year follow-up.

The apnea-hypopnea index was identified as an independent predictor of these adverse events, suggesting that monitoring and managing obstructive sleep apnea could be important for improving cardiac outcomes in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Relationship between severity of obstructive sleep apnea and adverse cardiac outcomes in non-diabetic patients presenting with myocardial infarction. Zhao, LP., Loh, K., Loo, G., et al.[2018]

Obstructive sleep apnea (OSA) affects about 9% of middle-aged men and 4% of women, with higher prevalence in specific groups like the elderly and those with heart conditions, highlighting its widespread impact on health.

OSA and insufficient sleep duration can lead to serious health issues, including cardiovascular disease, impaired cognitive function, and increased risk of accidents, emphasizing the importance of addressing sleep disorders for overall well-being.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration. Al Lawati, NM., Patel, SR., Ayas, NT.[2022]

In a study of 53 patients with obstructive sleep apnea (OSA), treatment with a simple continuous positive airway pressure (CPAP) device significantly reduced the apnea hypopnea index (AHI), arousal index (ArI), and oxygen desaturation index (ODI), indicating effective management of OSA symptoms.

The efficacy of the simple CPAP was comparable to traditional CPAP, with no significant differences in residual AHI, ArI, or ODI, suggesting that the simpler device can effectively replace traditional CPAP without compromising treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Efficacy of simple continuous positive airway pressure on patients with obstructive sleep apnea]. Qiu, ZH., Wei, QS., Wu, YX., et al.[2019]

In a study of 391 patients with minimally symptomatic obstructive sleep apnoea, CPAP therapy significantly reduced daytime sleepiness and improved self-assessed health status after 6 months of treatment.

However, CPAP did not show any improvement in the predicted 5-year vascular risk or its individual components, suggesting that while it helps with sleepiness, it may not affect long-term cardiovascular health.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Craig, SE., Kohler, M., Nicoll, D., et al.[2022]

In a study of 14 subjects with mild to moderate obstructive sleep apnea (OSA), using a shoulder-head elevation pillow (SHEP) resulted in a mean apnea-hypopnea index (AHI) reduction from 27 to 21, but was less effective than nasal continuous positive airway pressure (nCPAP), which achieved a mean AHI of 5.

While four subjects achieved treatment success with SHEP, nCPAP was successful in 12 subjects, indicating that elevated posture may serve as a second-line therapy for OSA, but it is not as effective as nCPAP.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Elevated posture for the management of obstructive sleep apnea. Skinner, MA., Kingshott, RN., Jones, DR., et al.[2018]

In a study of 102 adults with obstructive sleep apnea (OSA) followed for about 48 months, long-term use of CPAP did not lead to significant overall changes in apnea-hypopnea index (AHI) or oxygen desaturation index (ODI), indicating limited efficacy across the board.

However, CPAP treatment showed beneficial effects in specific subgroups, improving AHI in patients with moderate OSA and increasing nadir oxygen saturation in those with severe OSA, suggesting that CPAP may be more effective depending on the severity of the condition.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The changes of AHI after long-term CPAP in patients with comorbid OSA and cardiovascular disease. Cheng, Y., Ou, Q., Chen, B., et al.[2023]

Citations

1.

withpower.com

withpower.com/trial/phase-sleep-apnea-syndromes-4-2024-5e722

CATNAP MI for Obstructive Sleep Apnea

Research shows that treatments like continuous positive airway pressure (CPAP) can significantly reduce symptoms of obstructive sleep apnea, such as sleepiness ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/22837377/

Continuous positive airway pressure treatment of sleepy ...

Continuous positive airway pressure treatment improves the functional outcome of sleepy patients with mild and moderate obstructive sleep apnea.

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12292749/

Obstructive Sleep Apnea and Outcomes in Cardiac Surgery

The bar chart shows a higher AKI rate among OSA patients (25.2%) versus non-OSA patients (19.9%). The meta-analysis reported a pooled odds ratio ...

4.

ctv.veeva.com

ctv.veeva.com/study/cognition-after-osa-treatment-among-native-american-people-catnap

Cognition After OSA Treatment Among Native American ...

This study will explore the relationship between OSA and cognitive function and evaluate OSA as a mechanism for the strong association between sleep disorders ...

5.

clinicaltrials.gov

clinicaltrials.gov/study/NCT00089752

Continuous Positive Airway Pressure to Improve Milder ...

The purpose of this study is to determine whether functional status improves in individuals with milder obstructive sleep apnea (OSA) following continuous ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC5421476/

Association between Obstructive Sleep Apnea and Myocardial ...

MI was responsible for 29.5% of all 644 analysed outcomes. There is an association between OSA and MI, in male patients, and apnea and hypopnea index (AHI) are ...

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S0954611123001026

Obstructive sleep apnea modulates clinical outcomes post- ...

The aOR of in-patient mortality (n = 333 (1.1%)) was lower in those with OSA (aOR, 0.43; 95% CI, 0.38 to 0.49) compared to without-OSA (n = 1,102, 2.5%).

8.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03362385

Association of OSA and CPAP Therapy With Outcomes in ...

Cardiogenic shock (systolic blood pressure <90mmHg) · Cardiac arrest on admission or during hospitalization · Severe insomnia, chronic sleep deprivation, abnormal ...

9.

ahajournals.org

ahajournals.org/doi/10.1161/CIR.0000000000000988

Obstructive Sleep Apnea and Cardiovascular Disease

OSA may be implicated in an increased risk of major adverse cardiovascular events after percutaneous coronary intervention. Whether CPAP therapy ...